

Opioid Prescribing Task Force Issues Matrix – Acute Pain

Date/Location:

October 19/Spokane

Tech Experts:

Dr. Lynda Williamson, DO, Family Medicine & Sub-specialty in Chronic Pain Management

Dr. Matthew Layton MD, PhD, FACP, DFAPA, Clinical Professor, Elson Floyd College of Medicine, WSU

AMDG/CDC Recommendations:

AMDG—

- Explore non-opioid alternatives for treating pain and restoring function, including early activation.
- Check the PMP before prescribing.
- Help the patient set reasonable expectations about his or her recovery, and educate the patient about the potential risks and side effects of opioids.
- Assess function and pain at baseline and with each follow-up visit. Expect patients to improve and resume normal activities within days to weeks.
- Don't prescribe opioids for non-specific back pain, headaches, or fibromyalgia.
- Prescribe the lowest necessary dose for the shortest duration.
- Opioid use beyond the acute phase is rarely indicated. Consider tapering the patient off opioids as acute pain resolves; taper opioids by 6 weeks if pain is not improved or clinically meaningful functional improvement has not occurred.

CDC—

- Less than 3 days is usually sufficient, and more than 7 days is rarely needed.

1. What issues are there?	2. How can we address these issues?
How can we better regulate the use of opioids as a first-line treatment?	<ul style="list-style-type: none">• Consider language in the rules around the use of alternative therapies and when they should be explored in lieu of opioids (e.g. front-line pain control or when opioids are no longer effective in controlling pain or improving function)• Guidelines for short term (3 days; 7 days)• Recommendations for smooth hand-off

	<ul style="list-style-type: none"> • Check PMP; initiation of opioid treatment plan; screening questions for addiction flags; alternatives to opioid treatment • Reference the BREE collaborative for acute management; specific to dental but applicable to overall
Prescribing for non-specific medical events or diagnoses.	<ul style="list-style-type: none"> • Enhance language in general provisions about history and examination of patient to require documentation of a specific diagnosis?
Excessive prescribing (number of pills and/or days).	<ul style="list-style-type: none"> • Consider dosage limits for acute pain control, time limits for opioid therapy for acute pain, or a combination of the two. • Take back or accountability process • WA state allows partial re-fill
Ensuring patients are appropriate candidates for opioid therapy and at minimal risk for addiction.	<ul style="list-style-type: none"> • Requiring, as part of the history and examination of patients, an evaluation of comorbid health issues including mental health issues, a history of past substance abuse, and other prescribing. • Consider requiring a PMP query at initial prescription.
Type of opioids prescribed (immediate release vs. long-acting)	<ul style="list-style-type: none"> • Consider requirement to prescribe immediate release in acute phase.
Appropriate time for follow-up examination.	<ul style="list-style-type: none"> • Consider an outer limit (e.g. 2/4/6 weeks) when patient should be re-examined and reducing or terminating opioid therapy should be evaluated.
No pain management specialist should be responsible for peri-operative treatment alone	Collaboration between surgeon and pain specialist
ER patient presentation as pain may have a different root cause such as opioid withdrawal	ER physicians without a waiver can prescribe a treatment program Education issue
Operative versus non-operative pain requirements	
Naïve users	
Limits on pills versus days	Guidelines for days with opportunity for extension
Adolescent patients	Special guidelines for young patients
Pregnant patients and those non-opioid naïve	
Methadone patients and tolerance	
In-patient or ED non-opioid naïve	Anesthesia provider consultation

Screening questions during in-take process	
Pain catastrophizing scale (patient intake)	Predictor for patients at risk

3. What concerns/ impacts are there?	4. How might we mitigate these concerns?
Will regulating use of other modalities before opioids create “artificial” expectations about the number or duration of modalities tried before opioid therapy?	<ul style="list-style-type: none"> Consider what it means (and define, if possible) to exhaust other therapies.
Will limiting pill counts and/or days of prescriptions result in additional burden on patients and prescribers?	<ul style="list-style-type: none"> Can exceptions to any prescribing limits be crafted to rely on specific and appropriate documentation in the patient’s record?
Patients may experience some pain—what are reasonable expectations?	<ul style="list-style-type: none"> As part of prescribing process, require that prescribers explain risks and benefits of opioids, along with establishing realistic expectations for patient’s pain level.

li

5. What further information do we need?
<ul style="list-style-type: none"> • AMDG Guidelines • CDC Guidelines • State of Ohio Guidelines for Management of Acute Pain Outside of Emergency Departments • Tedesco et al; “Opioid Abuse and Poisonings: Trends in Inpatient and Emergency Department Discharge”; Health Affairs; 36:10; October 2017.

6. What is this group’s recommendation?

